News Image

Uncovering Dividend Opportunities with NYSE:PFE.

By Mill Chart

Last update: Jan 5, 2024

Take a closer look at PFIZER INC (NYSE:PFE), a stock of interest to dividend investors uncovered by our stock screener. NYSE:PFE excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.

Understanding NYSE:PFE's Dividend

ChartMill employs its own Dividend Rating system for all stocks. This score, on a scale of 0 to 10, is determined by evaluating different dividend factors, such as yield, historical performance, dividend growth, and sustainability. NYSE:PFE has been assigned a 7 for dividend:

  • PFE has a Yearly Dividend Yield of 5.84%, which is a nice return.
  • Compared to an average industry Dividend Yield of 4.29, PFE pays a better dividend. On top of this PFE pays more dividend than 97.52% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.43, PFE pays a better dividend.
  • PFE has been paying a dividend for at least 10 years, so it has a reliable track record.
  • PFE has not decreased their dividend for at least 10 years, which is a reliable track record.

How do we evaluate the Health for NYSE:PFE?

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has achieved a 6 out of 10:

  • PFE has a Altman-Z score of 2.39. This is in the better half of the industry: PFE outperforms 71.78% of its industry peers.
  • PFE has a better Debt to FCF ratio (7.78) than 81.19% of its industry peers.
  • PFE has a Current Ratio of 2.38. This indicates that PFE is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 2.05 indicates that PFE has no problem at all paying its short term obligations.

How do we evaluate the Profitability for NYSE:PFE?

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:PFE was assigned a score of 8 for profitability:

  • PFE has a better Return On Assets (4.87%) than 88.61% of its industry peers.
  • With an excellent Return On Equity value of 10.81%, PFE belongs to the best of the industry, outperforming 89.11% of the companies in the same industry.
  • PFE has a Return On Invested Capital of 5.70%. This is amongst the best in the industry. PFE outperforms 86.14% of its industry peers.
  • The last Return On Invested Capital (5.70%) for PFE is well below the 3 year average (16.16%), which needs to be investigated, but indicates that PFE had better years and this may not be a problem.
  • The Profit Margin of PFE (15.29%) is better than 90.10% of its industry peers.
  • PFE has a Operating Margin of 16.76%. This is amongst the best in the industry. PFE outperforms 86.14% of its industry peers.
  • In the last couple of years the Operating Margin of PFE has grown nicely.
  • PFE's Gross Margin of 59.32% is fine compared to the rest of the industry. PFE outperforms 68.81% of its industry peers.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Check the latest full fundamental report of PFE for a complete fundamental analysis.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

PFIZER INC

NYSE:PFE (4/26/2024, 7:09:35 PM)

After market: 25.45 +0.05 (+0.2%)

25.4

+0.14 (+0.55%)

PFE News

News Image8 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

News Image16 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Image21 hours ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

You'll get dividends and more with these great stocks.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

News Image2 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
News Image3 days ago - The Motley FoolWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

News Image3 days ago - BloombergPfizer’s First Gene Therapy Gets Approval for Clotting Disorder

Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.

News Image3 days ago - CNBCFDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. 

News Image3 days ago - Investor's Business DailyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy

Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

News Image3 days ago - Pfizer Inc.U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
PFE Links
Follow us for more